Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

3(75.0%)

Phase 1

1(25.0%)

4Total

Phase 2(3)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT00462943Phase 2Completed

Open Label Study of Subcutaneous Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Advanced CML

Role: collaborator

NCT00375219Phase 2Completed

Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation

Role: collaborator

NCT00114959Phase 2Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Role: lead

NCT00675350Phase 1Completed

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Role: lead

All 4 trials loaded